Novartis continues transformation into a leading medicines company with completion of the Alcon spin-off
Novartis has completed the spin-off of the Alcon eye care devices business. The successful execution of the Alcon spin-off allows Novartis to fully focus its capital allocation and management attention on medicines. The spin-off gives Novartis a financial profile closer to its pharmaceutical industry peers, including higher group margins. As a focused medicines company, Novartis is well-positioned for sustained top- and bottom-line growth.
09 Apr 19
